MEDVi Semaglutide Cost vs PlexusDx (2026): What You'll Actually Pay | PlexusDx

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re pricing MEDVi semaglutide against PlexusDx, the headline number is misleading on purpose. MEDVi advertises “starting at $179” on its main page, $149 on a live promo landing page, $249/month on a 3-month partner plan, and $219/month on a 6-month partner plan — but the refill rate after month one is $299/month on the standard path, and the tablet route starts at $249 with refills not publicly listed. PlexusDx prices its compounded GLP-1 protocols on one canonical page: Semaglutide Injection at $149/mo, Semaglutide Oral from $249/mo, Microdose GLP-1 Protocol at $129/mo flat, and GLP-Squared at $249/mo — all cash-pay, no membership, all 50 states (five require a live consult). This article walks the published MEDVi semaglutide pricing as of April 2026 and the side-by-side cost math against PlexusDx, so you can decide whether MEDVi’s intro hook actually wins on annualized cost.

MEDVi semaglutide pricing at a glance (April 2026)

MEDVi publishes compounded semaglutide across at least four live web properties at four different prices. The main MEDVi page lists compounded semaglutide injection at $179 for month one with $299/month refills from month two onward. A live promo landing page shows $149 for month one with the same $299 refill. A MEDVi-operated partner page advertises $249/month on a 3-month plan and $219/month on a 6-month plan — the lowest published ongoing rate we could verify on any MEDVi property. Compounded semaglutide tablets start at $249 for month one; tablet refill pricing is not publicly listed. MEDVi’s brand-name Wegovy routes use a separate “$99 membership + medication cost” structure that isn’t bundled into the compounded pricing above. PlexusDx Semaglutide Injection sits at $149/mo across five dose levels (0.25mg to 2.0mg weekly), and Semaglutide Oral starts at $249/mo across six dose levels (3mg to 24mg daily) — flat protocol pricing, no intro hook, no membership.

The annualized cost reconciliation: MEDVi vs PlexusDx

For a cash-pay patient with no insurance coverage for weight-loss drugs, here’s the math that actually matters. MEDVi standard path: $179 month one + ($299 × 11 refills) = $3,468/year. MEDVi $149 promo path: $149 + ($299 × 11) = $3,438/year — a $30 savings. MEDVi 6-month partner plan: $219 × 12 = $2,628/year if you renew the prepay twice. MEDVi tablets at $249 first month with unverified refill pricing — budget conservatively at $299/month thereafter. By comparison, PlexusDx Microdose GLP-1 Protocol at $129/mo flat totals $1,548/year. Semaglutide Injection at $149/mo totals $2,148–$2,748/year across the dose ladder. Semaglutide Oral from $249/mo totals roughly $2,508/year+ at the entry tier. GLP-Squared at $249/mo totals $2,148–$3,900/year. PlexusDx’s entry tier on Semaglutide Injection comes in roughly $720–$840 below MEDVi’s standard path, and the Microdose GLP-1 Protocol is roughly $1,920 below MEDVi’s standard path on a 12-month basis — without intro-pricing math or commitment plans.

Why MEDVi shows five different prices on five different pages

The pricing fragmentation isn’t accidental. MEDVi runs separate landing pages for separate ad campaigns, promotional cycles, and multi-month plan offers rather than consolidating pricing in one canonical place. The intro number depends on which page you land on; the refill number is consistent at $299/month on standard paths. If you arrive via an affiliate or partner property, you may see $249/month on a 3-month plan or $219/month on a 6-month plan instead. None of those rates is a “wrong” price — they’re all live — but the variation makes it hard to budget without verifying your specific plan terms at checkout. PlexusDx publishes all six Weight Management Protocol prices on individual product pages and keeps them stable: Semaglutide Injection $149/mo, Semaglutide Oral from $249/mo, Microdose GLP-1 Protocol $129/mo, Tirzepatide Injection $249/mo, Tirzepatide Oral $279/mo, and GLP-Squared $249/mo. The number on the product page is the number you’ll be charged.

Does the price go up at higher doses?

This is a question MEDVi answers explicitly: per its public pages, compounded semaglutide injection refills are described as “locked” at $299/month regardless of where you sit on the dose ladder. Patient reviews on third-party platforms generally corroborate that the refill rate stays flat as titration moves from 0.25mg up through 2.0mg weekly. If dose-locked pricing is decisive for your decision, confirm in writing with MEDVi support before paying — a flat refill on standard plans does not necessarily mean a flat refill on every promo or partner plan you might be enrolled in. PlexusDx Semaglutide Injection uses tiered protocol pricing across five dose levels: $179/mo at the entry tier and $229/mo at the top tier, with intermediate tiers between. The structure is published on the product page rather than disclosed at refill time. If you titrate to the maximum dose, your monthly is $229 — which is still below MEDVi’s flat $299 refill.

Injection vs oral: the cost gap MEDVi doesn’t fully publish

MEDVi’s compounded semaglutide tablet route starts at $249 for month one. Refill pricing for the tablet is not listed publicly on the main MEDVi page at the time of writing — meaning you’d need to confirm at checkout or in writing with MEDVi support what your month-two-onward charge will be. That’s a meaningful piece of missing information when you’re budgeting a 12-month protocol. PlexusDx Semaglutide Oral publishes pricing from $249/mo across six dose levels (3mg, 7mg, 14mg, 17mg, 21mg, and 24mg daily). If a daily oral GLP-1 fits your needle aversion or schedule better than a weekly injection, the oral path is the same compounded active ingredient delivered as a daily tablet. Compounded oral semaglutide is not the same as Rybelsus — Rybelsus is the FDA-approved branded oral semaglutide; compounded versions are pharmacy-prepared. We’re explicit about that distinction throughout PlexusDx materials.

What’s included in the price — and what isn’t

MEDVi’s all-inclusive pricing covers the clinician evaluation, compounded medication, supplies (syringes for injection routes), and shipping under one bill — no separate membership fee on the standard compounded paths. Brand-name Wegovy routes through MEDVi use a different “$99 membership + medication cost” model that isn’t bundled. PlexusDx pricing on every Weight Management Protocol is similarly all-inclusive: async provider consultation (or live consult in the five states that require it), prescription, compounded medication, and shipping — all in one number. There is no membership fee on any PlexusDx protocol. There’s also no insurance billing on either platform — both are cash-pay. HSA/FSA dollars generally apply to prescription GLP-1 medications under IRS rules when prescribed by a licensed clinician; using pre-tax dollars effectively reduces the out-of-pocket cost by roughly 22–35% depending on your tax bracket on either platform.

Compounded semaglutide is not FDA-approved — on either platform

This applies equally to MEDVi and to PlexusDx and is worth stating plainly. Compounded semaglutide is prepared by licensed U.S. compounding pharmacies, which are FDA-regulated entities, but the compounded formulations themselves are not FDA-approved finished drug products. Wegovy, Ozempic, and Rybelsus are the FDA-approved finished products containing semaglutide; only those branded products carry FDA approval. MEDVi’s core compounded paths and PlexusDx’s Semaglutide Injection and Semaglutide Oral protocols dispense compounded versions through licensed compounding pharmacies. The boxed warning for thyroid C-cell tumors applies to semaglutide based on rodent studies and applies whether the medication is the FDA-approved branded product or a compounded version. Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use semaglutide — on any platform.

The genetic baseline MEDVi doesn’t offer

One difference between MEDVi’s pricing model and PlexusDx’s isn’t about dollars — it’s about what informs your dose. GLP-1 response varies meaningfully across patients. Variants in GLP1R, FTO, MC4R, TCF7L2, and the GIPR rs1800437 marker are associated with different titration responses to semaglutide. The PlexusDx Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways, including 34 weight-management insights, so the prescribing clinician knows whether a faster-than-typical or slower-than-typical titration is more likely to fit your biology before week one. The test is $298 standalone or $99 as an add-on after your first month on any protocol — meaning a patient on Semaglutide Injection at the entry tier ($179/mo first month + $99 genetic test added in month two) lands at $278 in month two, still below MEDVi’s standard refill of $299 for the medication alone, with a genetic baseline included. MEDVi does not offer a comparable genetic stratification step.

Frequently asked questions

How much does MEDVi semaglutide cost per month?

Compounded semaglutide injection is $179 for month one and $299/month for refills on MEDVi’s main page. A live promo page shows $149 month one with the same $299 refill. A partner page advertises $249/month on a 3-month plan or $219/month on a 6-month plan. Tablets start at $249 with refill pricing not publicly listed. PlexusDx Semaglutide Injection is $149/mo across five dose levels with no intro hook.

Is the MEDVi $149 first-month price real or a bait-and-switch?

The $149 is real on live MEDVi promo landing pages, but the refill rate is still $299 starting month two. Year-one savings versus the $179 standard path are about $30. For comparison, PlexusDx Microdose GLP-1 Protocol at $129/mo flat totals $1,548/year — roughly $1,890 below MEDVi’s standard path on a 12-month basis with no intro pricing required.

Does MEDVi semaglutide cost more at higher doses?

MEDVi states publicly that compounded semaglutide injection refills are locked at $299/month regardless of dose, and patient reports generally corroborate that. PlexusDx Semaglutide Injection uses tiered protocol pricing of $149/mo across five dose levels — even at the top dose tier, the monthly is below MEDVi’s flat $299 refill.

Is MEDVi’s 6-month plan at $219/month actually cheaper than month-to-month?

Yes — the 6-month partner plan totals $1,314 over six months versus $1,674 on the standard $179/$299 path, a savings of roughly $360. The tradeoff is a six-month upfront commitment with stricter refund language. PlexusDx Semaglutide Injection at $179/mo on the entry tier totals $1,074 over six months with no commitment plan required.

Is MEDVi semaglutide injection or tablet cheaper?

Injection is cheaper at MEDVi: $179 first month and $299 refill, versus $249 first month for tablets with refill pricing not publicly listed. PlexusDx publishes both on canonical product pages: Semaglutide Injection at $149/mo and Semaglutide Oral from $249/mo, so you can compare both routes without checkout-time pricing surprises.

Is MEDVi semaglutide FDA-approved?

No. MEDVi’s core $179/$299 offer is compounded semaglutide, prepared by licensed U.S. compounding pharmacies but not an FDA-approved finished drug product. The same applies to PlexusDx Semaglutide Injection and Semaglutide Oral — both are compounded. Only Wegovy, Ozempic, and Rybelsus are FDA-approved finished semaglutide products. The boxed warning for thyroid C-cell tumors applies to semaglutide based on rodent studies regardless of whether the formulation is branded or compounded.

Can I use HSA or FSA dollars for MEDVi or PlexusDx semaglutide?

Yes on both platforms. Prescription GLP-1 medications for medical weight management are generally HSA/FSA-qualified expenses under IRS rules when prescribed by a licensed clinician. Pre-tax dollars cut effective cost by roughly 22–35% depending on your tax bracket — bringing PlexusDx Semaglutide Injection at the entry tier to an effective $116–$140/mo and MEDVi’s $299 refill to an effective $194–$233/mo.

Related reading on PlexusDx

Related reading on PlexusDx: Semaglutide Cost, GLP-1 Cost, Cheapest GLP-1, Compounded Semaglutide vs Wegovy.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing for MEDVi is based on its published rates as of April 2026; actual costs may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.